In: NEOPLASMA, vol. 52, no. 4
V. Dymicka-Piekarska - A. Butkiewicz - J. Matowicka-Karna - H. Kemona
Detaily:
Rok, strany: 2005, 297 - 301
O článku:
During platelet activation, P-selectin is translocated onto the
external platelet membrane. Surface exposure of P-selectin
is temporary, and the molecule undergoes endocytosis or shedding
to the circulation where it appears in a soluble form as
sP-selectin.
The aim of the study was to assess platelet activation based on
the level of soluble form of P-selectin (sP-selectin) in
colorectal cancer patients.
The study involved 22 surgically treated patients, divided into
two groups depending on histopathological malignancy
grade: group I - patients with low malignancy grade (G2), group
II - patients with high malignancy grade (G3). The examinations
were carried out three times: before surgery (A0) and 3 (A1) and
12 days (A2) after the surgery. Control group (C)
consisted of 20 healthy subjects. The sP-selectin level was
determined in the plasma using the ELISA Kit (Human
sP-selectin, R&D System).
In colorectal cancer patients sP-selectin concentration was
statistically significantly higher (69.25 ng/ml in group I and
66.50 ng/ml in group II) as compared to healthy subjects (46.01
ng/ml) (p<0.05), irrespective of malignancy grade. The surgical
procedure has a significant effect on the dynamics of changes in
the level of sP-selectin. Initially, 3 days (A1) after the
procedure, there is a decrease in the level of sP-selectin, but
after 12 days (A2) a rise is noted again, the level being the
highest
in group I. It indicates that the surgical procedure does not
totally eliminate the factors responsible for platelet activation
and did not normalize platelet activation.
Ako citovať:
ISO 690:
Dymicka-Piekarska, V., Butkiewicz, A., Matowicka-Karna, J., Kemona, H. 2005. Soluble P-selectin concentration in patients with colorectal cancer. In NEOPLASMA, vol. 52, no.4, pp. 297-301. 0028-2685.
APA:
Dymicka-Piekarska, V., Butkiewicz, A., Matowicka-Karna, J., Kemona, H. (2005). Soluble P-selectin concentration in patients with colorectal cancer. NEOPLASMA, 52(4), 297-301. 0028-2685.